NCCN Collaborates With Pfizer on Program Focused on Health Care Quality Improvement and Education

NCCN Collaborates With Pfizer on Program Focused on Health Care Quality 
Improvement and Education 
NCCN and Pfizer Will Elicit Proposals for Quality Improvement and
Education in Rare Cancer Types; Grants to Provide Funding for
Approximately Nine Proposals Focused on Patients With Renal Cell
Carcinoma or Hematologic Malignancies 
FORT WASHINGTON, PA  -- (Marketwired) -- 10/14/13 --  The National
Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP)
is collaborating with Pfizer Independent Grants for Learning & Change
(IGLC) to establish a peer-reviewed grant program to elicit proposals
focused on health care quality improvement and education projects. As
part of this program, the NCCN ORP and Pfizer will jointly issue a
Request for Proposals (RFP), focused on the development and adoption
of evidence-based initiatives to improve patient care and outcomes in
renal cell carcinoma and hematologic malignancies. 
The intent of the RFP is to encourage academic and community-based
organizations to submit proposals describing concepts and ideas for
design and implementation of systems or programs that close clinical
practice gaps and improve the care of patients with rare cancer types
through the establishment of education and support mechanisms for
community oncologists. It is expected that grants will fund
approximately nine projects. 
"NCCN is pleased to collaborate with Pfizer in this effort," said
Joan S. McClure, MS, Senior Vice President, Clinical Information and
Publications, NCCN. "Together, we will identify and fund projects
that interweave patient support and information, health care systems
issues, and broadening of clinician knowledge base to improve the
quality of care for individuals with rare cancers." 
The NCCN ORP and Pfizer will announce an RFP seeking concepts for
initiatives focusing on the following areas where there are gaps in

--  Health care provider education and incorporation of education into

--  Provider/patient communications and treatment decision-making

--  Increasing the use of evidence-based recommendations for management of
    renal cell carcinoma or hematologic malignancies

--  Information related to patient assistance programs and other patient-
    centered resources

Organizations may submit for one of two categories: renal cell
carcinoma or hematologic malignancies, which will include acute
lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and
non-Hodgkin's lymphomas (NHL). 
For the first time in its history, the NCCN ORP will draw upon the
expertise of investigators not only from the 23 NCCN Member
Institutions, but from all cancer centers across the United States,
including both academic and community settings. 
The NCCN ORP, organized to obtain funding to support scientifically
meritorious research studies at NCCN Member Institutions, will be the
lead organization for review and evaluation of applications. A review
committee, led by NCCN and including a medical representative from
Pfizer, will make decisions on which proposals will receive funding.
Grant funding will be provided by Pfizer IGLC. 
About the National Comprehensive Cancer Network 
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit
alliance of 23 of the world's leading cancer centers, is dedicated to
improving the quality, effectiveness, and efficiency of care provided
to patients with cancer. Through the leadership and expertise of
clinical professionals at NCCN Member Institutions, NCCN develops
resources that present valuable information to the numerous
stakeholders in the health care delivery system. As the arbiter of
high-quality cancer care, NCCN promotes the importance of continuous
quality improvement and recognizes the significance of creating
clinical practice guidelines appropriate for use by patients,
clinicians, and other health care decision-makers. The primary goal
of all NCCN initiatives is to improve the quality, effectiveness, and
efficiency of oncology practice so patients can live better lives. 
The NCCN Member Institutions are: Fred and Pamela Buffett Cancer
Center at The Nebraska Medical Center, Omaha, NE; City of Hope
Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and
Women's Cancer Center | Massachusetts General Hospital Cancer Center,
Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer
Center, Philadelphia, PA; Huntsman Cancer Institute at the University
of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert
H. Lurie Comprehensive Cancer Center of Northwestern University,
Chicago, IL; Memorial Sloan-Kettering Cancer Center, New York, NY;
Moffitt Cancer Center, Tampa, FL; The Ohio State University
Comprehensive Cancer Center - James Cancer Hospital and Solove
Research Institute, Columbus, OH; Roswell Park Cancer Institute,
Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and
Washington University School of Medicine, St. Louis, MO; St. Jude
Children's Research Hospital/The University of Tennessee Health
Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA;
University of Alabama at Birmingham Comprehensive Cancer Center,
Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF
Helen Diller Family Comprehensive Cancer Center, San Francisco, CA;
University of Colorado Cancer Center, Aurora, CO; University of
Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University
of Texas MD Anderson Cancer Center, Houston, TX; and
Vanderbilt-Ingram Cancer Center, Nashville, TN. 
Clinicians, visit Patients and caregivers, visit 
For more information about Pfizer Independent Grants for Learning &
The following files are available for download: 

--  PDF

Katie Kiley Brown
Press spacebar to pause and continue. Press esc to stop.